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Abstract
Background: Obsessive-compulsive disorder (OCD) is the fourth common psychiatric disorder. Among the anxiety disorders, OCD
has the least therapeutic response and 40-60% of OCD patients do not satisfactorily respond to the first-line standard treatment
known as treatment-resistant OCD. One of the best therapeutic strategies is the augmentation therapy, which is adding antipsy-
chotics to the standard treatment (SSRIs).
Objectives: This study was aimed at comparing the efficacy of Risperidone and Aripiprazole as augmentation therapy in the resis-
tant cases of obsessive-compulsive disorder.
Methods: In this double-blind randomized clinical trial, 100 patients with treatment-resistant OCD were diagnosed based on the
DSM-IV-TR and were followed for 12-weeks. The patients were randomly divided into two groups of Aripiprazole and Risperidone
and received an average daily dose of 5 mg and 1.5 mg for twelve weeks, respectively. The efficacy of treatment was measured and
compared by the Yale-brown obsessive-compulsive scale (Y-BOCS) at 4, 8 and 12 weeks.
Results: The mean Y-BOCS score of patients in Risperidone and Aripiprazole groups were 25.26± 4.17 and 25.02± 4.46; respectively
and had no significant difference (P = 0.79) at the beginning of the trial. At the end of the study (12th week), it was changed for the
Risperidone and Aripiprazole groups to 20.00± 4.45 and 16.24± 4.41, respectively (P < 0.001). Furthermore, there was a significant
decreasing trend of Y-BOCS scores in both groups, which was demonstrated by the repeated measurement analysis (P < 00.1).
Conclusions: It was found that both Aripiprazole and Risperidone could be effective in the treatment of treatment-resistant OCD
patients. However, Aripiprazole showed a higher efficacy compared to Risperidone.
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1. Background
Obsessive-compulsive disorder (OCD) is the fourth
common psychiatric disorder affecting 2-3% of the gen-
eral population (1). It is one of the chronic anxiety disor-
ders in which the patient suffers from obsessions or com-
pulsions. According to the DSM-IV-TR criteria, the obses-
sions are defined as persistent thoughts, urges, and im-
ages that are disturbing for the patient and cause anxiety
or distress. The compulsions are repetitive thoughts or
behaviors to cope with the anxiety caused by obsessions
(2). It is amongst the most disabling psychiatric disorders
(3). OCD patients experience a variety of chronic symp-
toms which affect their quality of life and interfere with so-
cial‚ occupational and marital functions (4). According to
the last study about the prevalence of psychiatric disorders
in Kashan, Iran, the prevalence of OCD was an estimated
6.8% and the third most common disorder after major de-
pressive disorder (MDD) and generalized anxiety disorder
(GAD) (5), which is three times more than its prevalence in
Iran (1.8%) (6). Therefore, providing a novel treatment for
these patients is one of the priorities for mental health pro-
grams in the city.
The first and standard treatment of OCD is selective
serotonin reuptake inhibitors (SSRIs), namely; Fluoxetine,
Citalopram, Fluvoxamine, and Sertraline. This disorder
has the least therapeutic response rate amongst the anx-
iety disorders. Forty to sixty percent of OCD patients do
not satisfactorily respond to the first-line standard treat-
ment (2, 7-9). The treatment-resistant OCD is defined as no
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response to the maximum and tolerable dosage of stan-
dard treatment after three months (2). These patients are
highly prone to the disability and complications caused by
OCD. In addition, there is a positive correlation between
the severity of OCD and the worsening of patient’s qual-
ity of life (10, 11). Therefore, it is necessary to investigate
more effective treatment modalities (2, 7-10) recently used
by clinicians (12).
Various strategies have been proposed to increase the
therapeutic response of treatment-resistant OCD (11). One
of the most common strategies is the augmentation ther-
apy by adding antipsychotics to the standard treatment
(2, 7-13). The priority of antipsychotics as augmenta-
tion therapy over placebo has been supported in differ-
ent meta-analyses (7-9, 14-16). For instance, Bloch et al.
(2006), in a systematic review of nine studies, compared
antipsychotics (Quetiapine, Olanzapine, Haloperidol and
Risperidone) with placebo and found that Haloperidol and
Risperidone were more effective than other agents in aug-
mentation therapy of treatment-resistant OCD (7). How-
ever, the question in most of these studies is whether all
the antipsychotics, as the augmentation therapy, have the
same therapeutic response (7, 14, 15). The different results
in these studies could be due to the differences in inclu-
sion criteria, study design, the severity of the disorder, the
duration of treatment with SSRI and comorbid conditions.
Therefore, it would be necessary to compare antipsychotic
agents after demonstrating the priority of antipsychotics
over placebo. To our knowledge, this has been investigated
in a few studies (17).
Maina et al. (18), in a single-blinded study in 2008,
compared the efficacy and tolerance of Risperidone and
Olanzapine as the augmentation therapy in treatment-
resistant OCD patients during eight weeks and did not
find any significant differences between them. In an-
other study in Turkey in 2011, Selvi compared the thera-
peutic response of Risperidone and Aripiprazole amongst
treatment-resistant OCD patients that showed Risperidone
is superior to Aripiprazole in augmentation therapy (19).
Risperidone has been studied in several studies and
appears to have more evidence of it compared to other
second-generation antipsychotics, like Quetiapine and
Olanzapine (7). In a meta-analysis, Dold et al. (9), in the
subgroup analysis showed that amongst different antipsy-
chotics, only the efficacy of Risperidone is significant.
On the other hand, the efficacy of Aripiprazole as aug-
mentation therapy of treatment-resistant OCD has been
supported in several recent studies (20-22). To our knowl-
edge, in Iran, only two studies have been conducted in
this regard, none of which had a head-to-head design. In
a study by Sayyah et al. (17), it was shown that Aripipra-
zole is superior to placebo. In another study, Shabani et al.
(23), found no evidence regarding the efficacy of Olanzap-
ine compared with placebo in treatment-resistant OCD.
Aripiprazole as the last second-generation antipsy-
chotics has a different chemical structure and showed
unique pharmacologic features (19). It is noted that
Risperidone is pharmacodynamically the antagonist of
dopamine receptor D2 and serotonin receptor 5-HT1a,
while Aripiprazole is a relative agonist of D2 and 5-HT1a
receptors and the antagonist of serotonin receptor 5-
HT2a (2). Therefore, comparing the efficacy of Risperi-
done, one of the first second-generation antipsychotics,
with Aripiprazole and having a slightly different pharma-
cologic structure could provide an opportunity to verify
the theories regarding the pathophysiology of obsessive-
compulsive disorder (19).
2. Objectives
This study designed to compare the efficacy of Risperi-
done and Aripiprazole in augmentation therapy of pa-
tients with treatment-resistant OCD in Kashan, Iran.
3. Methods
3.1. Subjects
This is a double-blind, randomized clinical trial that
was conducted at the Kashan University of Medical Sci-
ences (KAUMS), Kashan, Iran, in 2015. The convenient sam-
pling method was used. The patients were selected from
the outpatient clinic of Kargarnejad hospital, which is the
only governmental psychiatric referral hospital of KAUMS
with 100 existing beds.
The sample size for each group was an estimated 50 pa-
tients with a confidence interval of 95%, type II error of 20%,
and a minimum of 20% difference between the size of two









The patients were assessed by a checklist designed
based on the study protocol. For easy access to the pa-
tients, all of them were selected from referred patients in
the area covered by KAUMS, i.e., Kashan and Aran & Bid-
gol. The patients were recruited only after the goals of
the study, and its stages were explained for them by an ex-
pert psychiatrist. All patients signed the informed consent,
and the study was approved by the Ethics Committee of
KAUMS with the file number p/29/5/1/2056. The study was
funded by the vice chancellor of research at KAUMS. All the
ethical issues such as informed consent, plagiarism, du-
plication and/or submission were considered. The respon-
dents were anonymous and participated willingly in this
study. The study protocol was registered in Iranian registry
2 Iran Red Crescent Med J. 2018; 20(7):e41418.
Assarian F et al.
of clinical trials (IRCT) portal with “IRCT2015110424882N1”
code.
The inclusion criteria for this study were OCD pa-
tients aged 18 and above with the Yale-brown obsessive-
compulsive scale (Y-BOCS) score of 16 or more and after at
least three months of therapy with a maximum and toler-
able dose of an SSRI (2).
The exclusion criteria were breastfeeding and preg-
nancy, not using safe contraceptive methods, drugs and
alcohol abuse during the last 6-months, receiving psy-
chotherapy during the study, any known disorder in DSM-
IV-TR axis I and II such as major depressive disorder (MDD),
personality disorder or mental retardation, any physical
disease impeding the use of Risperidone or Aripiprazole,
severe adverse effects to administered drugs and dropped
out for more than four weeks during the trial.
3.2. Study Design and Procedures
This study was a double-blind, randomized clinical
trial on 100 patients with refractory OCD, who were fol-
lowed for 12-weeks. The patients filled a demographic ques-
tionnaire and then went through a clinical interview. The
diagnosis of OCD and comorbid conditions were based on
the structured clinical interview for DSM IV-TR axis I disor-
ders, clinical trials version (SCID-CT) and structured clin-
ical interview for DSM IV-TR axis II personality disorders
(SCID-II) (24, 25). There were eight visits for each patient
during the study. The first visit was for randomization and
receiving the treatment, the second at the end of the first
week, the third at the end of the second week, and then ev-
ery two weeks until the end of the study (12th week). On
all the visits, the checklist for drug side effects was com-
pleted and in case of adverse reactions, either the dosage
was decreased or other medications such as Propranolol,
Lorazepam, and Biperidine was used to control it. On the
fourth, eighth, and 12th visits, Y-BOCS score, was measured
by the colleague psychiatrist.
To randomize the treatment allocation, the permuted
block randomization method was used. Both the treat-
ments were provided in identical covers so that the pa-
tients and the physician were not aware of it. Aripipra-
zole (Sobhan Darou Co., Tehran, Iran) started with a 2.5 mg
daily dose and was gradually increased to 10 mg daily by
the end of the second week. Risperidone (Sobhan Darou
Co., Tehran, Iran) initiated with a 1 mg daily dose and was
gradually increased to 2 mg daily by the end of the second
week. The dosing was on the basis of previous studies (18,
22).
In this study, the questionnaires used were Yale-brown
obsessive compulsive scale and a demographic survey.
The data regarding the history of the disease, received
treatment and the side effects of medications were also
recorded.
The Yale-brown obsessive-compulsive scale (Y-BOCS)
was developed at the end of the 1980s to quantify the sever-
ity of OCD symptoms. It consists of ten questions with the
first five on obsessions and the remainder on compulsions.
Each question has a score of 0 to 4 so that the total score
would range between 0 and 40. The usual score of OCD
patients lie between 16 and 30, and a score of 16 is an ap-
propriate threshold for beginning medical treatment. In
this study the Persian version of Y-BOCS was used, which
has shown good validity and reliability. In a study of 140
OCD patients and 30 controls, the test-retest reliability and
the internal consistency score of this scale was reported to
be 0.99 and 0.95, respectively (26).
3.3. Statistical Analysis
To examine the efficacy of drugs over time and to com-
pare it between two mutually exclusive assigned drugs, the
repeated measure analysis was used. This method has the
advantages of reducing type Ierror, requiring smaller sam-
ple size and the ability to both compare the efficacy be-
tween the two groups and examine it within each group
over time.
4. Results
Among the referred patients, 61% (100 patients) agreed
to participate in this RCT, which were assigned to two equal
groups (n = 50).
The rate of dropout in every group was 13%. In the
Aripiprazole group, three cases were excluded because of
akathisia and three cases left the trial because of non-
compliance without any reason. In the Risperidone group,
three cases were excluded because of the sedation side ef-
fects, two cases because of tremor and two cases left the
trial because of non-compliance without any reason.
According to the study protocol, severe side effects
were considered as the exclusion criteria and were substi-
tuted with new cases. In this study, the per-protocol analy-
sis was used. There was no significant difference found be-
tween the two groups in this regard.
The sampling processes are presented in Figure 1.
The mean age in the Risperidone group was 36.42 ±
10.58 years and in the Aripiprazole group 40.06 ± 10.54
years with no significant difference (P = 0.09). As shown
in Table 1, both groups were comparable for sex, age and
marital status.
There was no significant difference between the Y-BOCS
score of the two groups at the baseline. It is presented in
Table 2.
The prevalence of depression in the Risperidone and
Aripiprazole group was 12% and 8%, respectively (P = 0.50).
The prevalence of anxiety was 10% and 5% in Risperidone
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164 OCD Treatment-
Resistant Had Inclusion 
Criteria




Method with Ratio of 1 
for Each Trial Group
50 Received Aripiprazole 
44 (87%) Completed Trial
Six New Cases Added to 
This Group
6 (13%) Dropped Out
50 Received Risperidone
43 (87%) Completed Trial
Seven New Cases Added to 
This Group
7 (13%) Dropped Out
64 (39%) Refused Trial
Figure 1. Sampling Flowchart of Treatment-resistant OCD Patients That Participated in the Aripiprazole vs. Risperidone Trial
Table 1. Demographic Characteristics of Study Population
Variable Study Group P Valuea
Risperidone Aripiprazole Total
Sex, N. (%) 0.84
Male 22 (44) 21 (42) 43
Female 28 (56) 29 (58) 57
Age, Mean (SD) - 0.26
Male 36 (10.2) 37.71 (10.74)
Female 36.62 (11) 41.76 (10.29)
Marital status, N. (%) 0.5
Single 14 (28) 9 (18) 23
Married 35 (70) 40 (80) 75
Divorced 1 (2) 1 (2) 2
aP < 0.05 was considered significant.
and Aripiprazole groups, respectively, with no significant
difference (P = 0.46). The most common type of obsession
in patients of both groups was contamination, and the
most common type of compulsion was washing. There was
no significant difference between the two groups in terms
of the type of OCD. 56% of patients in the Risperidone
group and 46% in the Aripiprazole group received Fluox-
etine with the rest receiving Fluvoxamine in each group.
The two groups were statistically the same with regards to
the SSRI agents used (P = 0.32).
To perform the repeated measure analysis, the equal-
ity of covariance as the required assumption was checked
with Box’s test. Then to examine within the subjects effects,
the compound symmetry assumption was checked with
Mauchly’s test. Due to the significant result of this test and
rejection of the compound symmetry, multivariate results
were considered. It showed different effects among the
times (with respect to Pillai’s Trace test, P < 0.001). There-
fore, the efficacy of both administered drugs changed sig-
nificantly over time (see Figure 1). When the mean Y-BOCS
scores were compared between the two groups, it was
found to be more evident for Aripiprazole than Risperi-
done. In addition, there was an interaction between time
and administered drug (P < 0.001). As shown in Figure 1,
the increasing trend of efficacy over time for Aripiprazole
is superior to Risperidone.
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Figure 2. The Trend of Changes in Mean Y-BOCS Scores of Patients in Risperidone
and Aripiprazole Groups Over Time
Table 2. The Efficacy of Treatment Measured by Yale-Brown Obsessive-Compulsive
Scale (Y-BOCS) Score Before Treatment, at the End of 4, 8, and 12 Weeks
The Y-BOCS Score Group P Valuea
Risperidone Aripiprazole
Before treatment 4.17± 25.26 4.46± 25.02 0.79
4th week 4.11± 24.1 4.54± 22.62 0.09
8th week 4.21± 22.96 4.85± 20.26 0.004
12th week 4.45± 20.0 4.41±16.24 < 0.001
Total 4.16± 23.08 4.49± 21.03 0.02
P value < 0.001 < 0.001 -
aP < 0.05 was considered significant.
5. Discussion
In this study, the efficacy of adding Aripiprazole
or Risperidone to the standard treatment of treatment-
resistant OCD was studied in 100 patients. It was demon-
strated that Aripiprazole and Risperidone lead to a signif-
icant decrease in the Y-BOCS score of patients, which was
more prominent in the Aripiprazole group.
This finding is consistent with the results of other stud-
ies. In a pilot study of Delle et al. (27) in 2009, the stud-
ied efficacy of adding Aripiprazole with a dose of 5 to 20
mg per day to the standard treatment (SSRIs) in 20 OCD pa-
tients showed a significant decrease in the severity of OCD.
In a case series study conducted by Higuma et al. (28) in
2012 on 13 patients with treatment-resistant OCD, combina-
tion therapy with Aripiprazole (3 - 12 mg/day) and an SSRI
caused a significant decrease in the Y-BOCS score of the pa-
tients. In a double-blind study, Sayyah et al. (17) in 2012
followed 39 OCD patients in two groups receiving placebo
and Aripiprazole (10 mg/day) for 12 weeks. It was shown
that Aripiprazole led to a significant decrease in Y-BOCS
score compared with placebo. Pessina et al. (20) in an open-
label study added a 5 - 20 mg daily dose of Aripiprazole
to SSRI in 12 patients with treatment-resistant OCD and af-
ter 12-weeks observed a significant decrease in the Y-BOCS
score of the patients. Another open-label study in 2005 by
Connor et al. on 18 OCD patients treated with a daily dose
of 10-30 mg Aripiprazole for eight weeks showed 43% of pa-
tients had at least 30% decrease in their Y-BOCS score at the
end of the study (29). Similar findings have been reported
in other studies (30-38).
Risperidone has also proved quite effective in the treat-
ment of OCD symptoms. In a study by Maina et al. (18), in
a single-blind study in 2008, 96 treatment-resistant OCD
patients were treated with a daily dose of 1 - 3 mg Risperi-
done combined with SSRIs for eight weeks. There was a
significant decrease in the Y-BOCS scores of the patients.
Erzegovesi et al. (39) in a double-blind placebo-control
study in 2005 studied the efficacy of low doses of Risperi-
done added to the SSRI regimen (Fluvoxamine) in 45 pa-
tients with treatment-resistant OCD. It was demonstrated
that even very low doses of Risperidone (0.5 mg/day) for
six weeks can improve OCD symptoms. In Li et al. (40)
crossover study in 2005 on 12 OCD patients observed that
the nine-week treatment with a daily dose of 1 - 3 mg
Risperidone, besides its positive effect on OCD, improves
the depressive mood of patients. Similar findings to our
study and aforementioned studies have been reported in
the literature (10, 41-45).
Despite differences in treatment duration, therapeu-
tic response and the Y-BOCS baseline score between previ-
ous studies and this study, their results were consistent.
However, it was also found in our study that treatment-
resistant OCD patients under treatment of Aripiprazole
had a greater decrease in their Y-BOCS score than Risperi-
done. To our knowledge, there was only one study regard-
ing the comparison between Risperidone and Aripipra-
zole as the augmentation therapy of treatment-resistant
OCD patients, which is inconsistent with our findings. In
a single-blind randomized study by Selvi et al. (19), in
2011, 41 patients with treatment-resistant OCD were treated
with Aripiprazole (15 mg/day) or Risperidone (3 mg/day)
for eight weeks. It was found that patients treated with
Risperidone had a greater decrease in their Y-BOCS score.
This difference could be due to a difference in doses, 1.5 ver-
sus 3 mg per day for Risperidone and five versus 15 mg per
day for Aripiprazole. Furthermore, it could also emanate
from the fact that different doses can cause different effects
of used drugs on serotonin and dopamine receptors.
Different neurotransmitter systems are involved in the
etiology of OCD, of which the role of serotonergic system
has been well elucidated (46). However, other neurotrans-
mitters like dopaminergic system are also probably in-
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volved in OCD pathogenesis, so that antagonistic effects of
antipsychotics increase the efficacy of SSRIs in treatment-
resistant OCD (27). In PET (Positron Emission Tomogra-
phy) studies, it has been observed that low doses of an-
tipsychotics cause high levels of 5-HT2 receptor anatomiza-
tion, while it is only with high doses of antipsychotics that
remarkable dopaminergic antagonistic effects have been
seen (47). Therefore, it appears that the role of serotoner-
gic system is more dominant in this study.
Another justification for the inconsistency seen be-
tween the results of our study and Selvi et al. study (19)
is that there was a higher dropout rate in the Selvi study
amongst the Aripiprazole group compared to Risperidone,
while it was identical in our study. Compared to previ-
ous studies, low doses of the drugs was a limitation of this
study. It was because lower doses are associated with a
lower rate of adverse effects and better compliance. There
are also limitations due to volunteer bias. As mentioned
before, 39% of patients refused to participate in this trial
that could cause selection bias. The sampling area of this
study was restricted to only two cities in Iran with a high
homogeneity of cultural and social factors. This might
limit the generalization of findings to other study popula-
tions. However, the results of this study can be notable in
the evaluation of different neurotransmitter systems roles
in the treatment of treatment-resistant OCD.
The strengths of this study were the double-blind de-
sign, adequate sample size and the comparison between
two antipsychotic drugs in a head-to-head design for the
first time in Iran.
5.1. Conclusion
In this study, it was found that both Aripiprazole
and Risperidone could be effective in the treatment of
treatment-resistant OCD. It was also demonstrated that
Aripiprazole has a higher efficacy in treating treatment-
resistant OCD.
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